when were glp 1 agonists approved for weight loss Rx Trends: Real-World Data on GLP-1s - The Landscape Of GLP-1 Receptor
Description
As global demand rises for effective metabolic therapies, GLP-1 drug development remains one of the fastest-growing segments in biopharma innovation
GLP-1 medications can provide major health benefits, but recent studies have raised questions about a possible link with NAION, a rare optic nerve condition that can cause sudden vision loss
The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).
Eli Lillys first nine months of 2025 underscored the scale of the GLP-1 surge: Mounjaro and Zepbound generated $39.5 billion in revenue and surpasses Mercks Keytruda as the worlds best-selling medicine[5]
No injections
Quality Assurance & Verification
